#United States #Rockville #Metabolomics #AHARA Mushrooms #Reishi extract

Unveiling AHARA Mushrooms' Revolutionary Metabolomic Analysis

AHARA Mushrooms, a pioneering biotech startup based in Rockville, Maryland, has made a significant leap in the field of natural supplements by releasing the results of the most extensive metabolomic analysis ever performed on a mushroom supplement. This monumental study was conducted by one of the world's foremost metabolomics laboratories and utilized advanced dual-panel CE-MS and LC-MS mass spectrometry techniques.

The research uncovered over 1,000 uniquely identified compounds from AHARA's proprietary Reishi extract, including significant molecules such as adenosine precursors, GABA (gamma-aminobutyric acid), glycine, oleamide, a variety of ganoderic acids, short-chain fatty acids, and bioactive peptides. These compounds span 17 distinct metabolic pathways, including key processes like the GABAergic, cholinergic, anti-inflammatory, and neuroprotective pathways, all of which are naturally found in AHARA's unique water-based extract.

Among the critical findings was the role of adenosine, a vital signal for sleep pressure in the brain, enhanced by adenine and hypoxanthine present in the extract. GABA, the brain's main inhibitory neurotransmitter, is coupled with neurosteroid potentiators that amplify its effects, improving sleep and reducing anxiety. Glycine, known for its role as an inhibitory neurotransmitter and NMDA receptor co-agonist, is also featured prominently, contributing to sleep quality alongside oleamide, which signals the body to prepare for sleep.

Furthermore, the presence of 26 ganoderic acids, exclusive anti-inflammatory triterpenoids unique to Reishi mushrooms, is pivotal in reducing inflammation that disrupts sleep, exacerbates anxiety, and harms neurons. These findings challenge the longstanding assertion in the mushroom industry that the extraction of ganoderic acids requires harsh chemical solvents. Unlike traditional methods, AHARA's innovative water-based extraction technique successfully recovered these beneficial compounds without utilizing ethanol or methanol, thereby preserving the complete array of bioactives in a single aqueous extract.

Dr. Subhas Malghan, a key figure in this groundbreaking development, has led AHARA in applying advanced nanotechnology to enhance the bioavailability of these compounds. The inclusion of nanofibers ensures that the full spectrum of compounds is absorbed through mucosal tissues, bypassing first-pass metabolism which can diminish efficacy.

In an interview, Aaron Grimes, co-founder of AHARA Mushrooms, emphasized the integrity of their production process: "Every step of our process is American. We grow and extract our mushrooms in the U.S., and validate our products at a globally recognized metabolomics laboratory. We’re not simply importing extracts and labeling them; we maintain control over our entire supply chain and the science that underpins it."

AHARA Mushrooms was established by Ajay Malghan (MFA), Dr. Subhas Malghan (Ph.D. from UC Berkeley), and Aaron Grimes (MBA). The full findings of their metabolomic study, alongside their innovative mushroom therapeutics, can be explored in detail at their website, aharamushrooms.com.

With this publication, AHARA is poised to not only set a new standard in the mushroom supplement industry but also to elevate the discussion around the role of metabolomics in health and wellness strategies.